Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-06-14
Target enrollment:
Participant gender:
Summary
Angiogenesis, the development of new blood vessels, plays an important role in the disease
development and tumor growth in many solid organ malignancies. Bevacizumab was the first
anti-angiogenic drug to be approved in solid tumors and has shown advantageous activity with
multiple tumor types. However, the responses from Bevacizumab are often transient due to the
tumor's manipulative abilities to circumvent the usual pathways to find salvage pathways
instead.
Nintedanib has demonstrated anti-tumor activity in non-squamous non-small cell lung cancer,
colorectal cancer, ovarian cancer, and renal cell cancer. The combination of Bevacizumab and
Nintedanib are being proposed to target the tumor's manipulation processes to generate
alternate pathways for angiogenesis thus creating a potential benefit to delay tumor growth.